159 related articles for article (PubMed ID: 38694883)
1. Clozapine clinical toolkit optimizes inpatient clozapine monitoring.
Gessner B; Carter M; Rahnama K; Almeida A; Borralho C; Mihic T; Ng JCY; Puyat JH; Russolillo A; Halpape KC
Ment Health Clin; 2024 Apr; 14(2):85-91. PubMed ID: 38694883
[TBL] [Abstract][Full Text] [Related]
2. Evaluating Monitoring Guidelines of Clozapine-Induced Adverse Effects: a Systematic Review.
Smessaert S; Detraux J; Desplenter F; De Hert M
CNS Drugs; 2024 Feb; 38(2):105-123. PubMed ID: 38236524
[TBL] [Abstract][Full Text] [Related]
3. Incidence and Management of Clozapine-Induced Myocarditis in a Large Tertiary Hospital.
Higgins JM; San C; Lagnado G; Chua D; Mihic T
Can J Psychiatry; 2019 Aug; 64(8):561-567. PubMed ID: 30599763
[TBL] [Abstract][Full Text] [Related]
4. Clozapine treatment: Ensuring ongoing monitoring during the COVID-19 pandemic.
Nystazaki M; Alevizopoulos G
Psychiatriki; 2021 Jul; 32(2):165-166. PubMed ID: 33759812
[TBL] [Abstract][Full Text] [Related]
5. Assessing prescribing practices of clozapine before and after the implementation of an updated risk evaluation and mitigation strategy.
Curry B; Palmer E; Mounce C; Smith G; Shah V
Ment Health Clin; 2018 Mar; 8(2):63-67. PubMed ID: 29955547
[TBL] [Abstract][Full Text] [Related]
6. Clozapine monitoring at a specialised psychiatric hospital: A retrospective chart review.
Daniels MV; Ramlall S
S Afr J Psychiatr; 2023; 29():2039. PubMed ID: 37928939
[TBL] [Abstract][Full Text] [Related]
7. [Development and implementation of clozapine protocol in patients with schizophrenia in Greece].
Nystazaki M; Karanikola M; Gartzoni V; Georgou A; Tolia S; Liapis C; Psomiadi M; Alevizopoulos G
Psychiatriki; 2020; 31(1):70-81. PubMed ID: 32544078
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of major adverse events of clozapine based on accordance to an international titration guideline.
Nuebel M; Leung JG; Hughes C; McGrane I
Ment Health Clin; 2024 Jun; 14(3):204-211. PubMed ID: 38835819
[TBL] [Abstract][Full Text] [Related]
9. No adverse events were observed in clozapine-treated patients on extended hematologic monitoring intervals during the coronavirus pandemic in four psychiatric centers in Japan.
Hata M; Fujimoto M; Kanai K; Yoshiyama K; Nakatani Y; Nakabayashi D; Maemura S; Kawata S; Hakozaki T; Nishikura S; Umemoto A; Sasada T; Iwata K; Tanaka H; Mamoto A; Toi Y; Taniguchi N; Saito M; Kimura Y; Kishimoto K; Hayami M; Ikeda M
Neuropsychopharmacol Rep; 2021 Jun; 41(2):179-184. PubMed ID: 33606356
[TBL] [Abstract][Full Text] [Related]
10. Current practice for clozapine-induced leukopenia in Japanese psychiatric hospitals: A nationwide survey.
Niitsu T; Yasui-Furukori N; Inada K; Kanazawa T; Iyo M; Ueno T; Hashimoto R
Schizophr Res; 2024 Jun; 268():82-87. PubMed ID: 38038428
[TBL] [Abstract][Full Text] [Related]
11. Clozapine-induced agranulocytosis and leukopenia: Incidence, associated factors, and rate of hematologic adverse-effects monitoring in psychiatric out-patient services in Thailand.
Tunsirimas N; Pariwatcharakul P; Choovanichvong S; Ratta-Apha W
Asian J Psychiatr; 2019 Mar; 41():13-16. PubMed ID: 30856469
[TBL] [Abstract][Full Text] [Related]
12. [Safety aspects during treatment with clozapine. : Monitoring and rechallenge - a narrative review].
Berger SJ; Hofer A
Neuropsychiatr; 2023 Sep; 37(3):130-135. PubMed ID: 37389803
[TBL] [Abstract][Full Text] [Related]
13. Patient safety: adverse effects of Clozapine and their management at the Psychiatric Hospital Ghrasia in Yogyakarta, Indonesia.
Rahajeng B; Sari BC; Maziyyah N
J Med Life; 2023 Nov; 16(11):1652-1657. PubMed ID: 38406784
[TBL] [Abstract][Full Text] [Related]
14. Clozapine and hematologic adverse reactions: Impact of the Risk Evaluation and Mitigation Strategy program.
Borrelli EP; Lee EY; Caffrey AR
Ment Health Clin; 2020 May; 10(3):70-75. PubMed ID: 32420002
[TBL] [Abstract][Full Text] [Related]
15. Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and use.
Remington G; Lee J; Agid O; Takeuchi H; Foussias G; Hahn M; Fervaha G; Burton L; Powell V
Expert Opin Drug Saf; 2016 Sep; 15(9):1193-203. PubMed ID: 27207070
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of clozapine-associated inflammation and related monitoring.
Leung JG; Zhang L; Markota M; Ellingrod VL; Gerberi DJ; Bishop JR
Pharmacotherapy; 2023 Dec; 43(12):1364-1396. PubMed ID: 37842767
[TBL] [Abstract][Full Text] [Related]
17. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.
Barber S; Olotu U; Corsi M; Cipriani A
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD006324. PubMed ID: 28333365
[TBL] [Abstract][Full Text] [Related]
18. [Safety aspects during treatment with clozapine: : Adverse effects, titration, and therapeutic drug monitoring - a narrative review].
Berger SJ; Hofer A
Neuropsychiatr; 2023 Sep; 37(3):122-129. PubMed ID: 37349671
[TBL] [Abstract][Full Text] [Related]
19. Clozapine: balancing safety with superior antipsychotic efficacy.
Meltzer HY
Clin Schizophr Relat Psychoses; 2012 Oct; 6(3):134-44. PubMed ID: 23006238
[TBL] [Abstract][Full Text] [Related]
20. A Guide to the Management of Clozapine-Related Tolerability and Safety Concerns.
Citrome L; McEvoy JP; Saklad SR
Clin Schizophr Relat Psychoses; 2016 Jul; ():. PubMed ID: 27454214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
